Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the ...
The Dana-Farber-co-led phase 3 IMvigor011 trial results show that periodic ctDNA screening after surgery can help guide a ...
Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo –– ...
Zacks Investment Research on MSN
Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last?
Personalis PSNL shares ended the last trading session 20.5% higher at $10.28. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...
MVZ HPH Institute for Pathology and Hematopathology GmbH, today announced the availability of HPH MRD, a new tumor-informed ...
4d
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has been named ...
The teclistamab-cqyv and daratumumab regimen achieved a 100% overall response rate and MRD negativity in newly diagnosed ...
A cancer treatment laboratory in Lewisville recently made a medical breakthrough that could greatly decrease the risk of the ...
Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback